Infliximab biosimilar - Reliance Life Sciences

Drug Profile

Infliximab biosimilar - Reliance Life Sciences

Alternative Names: BOW-015; Infimab; R-TPR-015

Latest Information Update: 01 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EPIRUS Biopharmaceuticals
  • Developer EPIRUS Biopharmaceuticals; Sun Pharmaceutical Industries
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Marketed Rheumatoid arthritis
  • Preregistration Autoimmune disorders

Most Recent Events

  • 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
  • 18 Jul 2016 Reliance Life Sciences acquires Infliximab biosimilar from EPIRUS Biopharmaceuticals (Epirus Biopharmaceuticals 8-K, July 2016)
  • 09 May 2016 Infliximab biosimilar - EPIRUS Biopharmaceuticals is available for licensing in USA, Latin America, Europe as of 09 May 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top